Dr. Aaron Milstone, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,085
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TN license 27593 -
Critical Care Medicine (Internal Medicine) Physician
TN license 27593 -
Internal Medicine Physician
TN license 27593 -
Sleep Medicine (Internal Medicine) Physician
TN license 27593
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
- Williamson Medical Center Franklin, TN
Medical groups
- Williamson Medical Group, LLC (69 clinicians)
- Maui Medical Group Inc (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,085
- Services billed
- 4,107
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | 1,202 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,101 | 718 |
| Test to determine lung volumes using gas dilution or washout | 152 | 151 |
| Test to examine how well the lungs exchange gases | 149 | 148 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 130 | 126 |
| New patient office or other outpatient visit, 45-59 minutes | 129 | 129 |
| Therapy procedure using a positive pressure ventilator | 120 | 119 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 114 | 112 |
| Sleep study in sleep lab (6 years or older) | 100 | 98 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 70 | 70 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Franklin, TN | 367 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Franklin, TN | 338 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Franklin, TN | 216 |
| Prednisone Other prescribers in Franklin, TN | 166 |
| Montelukast Sodium Other prescribers in Franklin, TN | 155 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Franklin, TN | 95 |
| Zolpidem Tartrate Other prescribers in Franklin, TN | 88 |
| Trazodone Hcl Other prescribers in Franklin, TN | 75 |
| Clonazepam Other prescribers in Franklin, TN | 73 |
| Doxepin Hcl Other prescribers in Franklin, TN | 68 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 45 payments worth $19,376 in total to this clinician.
| Verona Pharma, Inc. | $11,580 |
|---|---|
| Mylan Inc. | $2,476 |
| Chiesi USA, Inc. | $2,457 |
| Viatris Specialty LLC | $2,022 |
| AstraZeneca Pharmaceuticals LP | $182 |
| GlaxoSmithKline, LLC. | $155 |
| Inspire Medical Systems, Inc. | $133 |
| Csl Behring | $85.67 |
| Honoraria | $9,000 |
|---|---|
| Consulting Fee | $4,498 |
| Travel and Lodging | $4,056 |
| Food and Beverage | $1,183 |
| Education | $600 |
| Compensation for services other than consulting (speaking, faculty) | $39.20 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Verona Pharma, Inc. Nov 18, 2025 | Honoraria Ohtuvayre · Pulmonary/Respiratory Diseases | $6,000 |
| Verona Pharma, Inc. Oct 16, 2025 | Honoraria Ohtuvayre · Pulmonary/Respiratory Diseases | $3,000 |
| Mylan Inc. Apr 4, 2025 | Consulting Fee YUPELRI · Anticholinergics, Inhaled | $2,476 |
| Chiesi USA, Inc. Jan 24, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $2,368 |
| Viatris Specialty LLC Jul 15, 2025 | Consulting Fee YUPELRI · Anticholinergics, Inhaled | $2,022 |
| Verona Pharma, Inc. Nov 18, 2025 | Travel and Lodging Ohtuvayre · Pulmonary/Respiratory Diseases · travel to Lexington, KY | $1,688 |
| Verona Pharma, Inc. Mar 19, 2025 | Education Ohtuvayre · Pulmonary/Respiratory Diseases | $600 |
| Verona Pharma, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) Ohtuvayre · Pulmonary/Respiratory Diseases | $39.20 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 24 industry-funded studies in 2025, from 9 companies. The companies reported $441,080 in research payments for these studies, mostly to the institutions running them.
- A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
AstraZeneca Pharmaceuticals LP - A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibro…
Boehringer Ingelheim Pharmaceuticals, Inc. - Verona
Verona Pharma, Inc. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.